A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.
about
The Renin-Angiotensin-aldosterone system in vascular inflammation and remodelingReview of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studiesAdrenal Diagnostics: An Endocrinologist's Perspective focused on HyperaldosteronismAldosterone synthase inhibition in humansIs there a new dawn for selective mineralocorticoid receptor antagonism?Beneficial effects of proanthocyanidins in the cardiac alterations induced by aldosterone in rat heart through mineralocorticoid receptor blockadePrimary Aldosteronism: Changing Definitions and New Concepts of Physiology and Pathophysiology Both Inside and Outside the Kidney.A high-throughput chemical screen with FDA approved drugs reveals that the antihypertensive drug Spironolactone impairs cancer cell survival by inhibiting homology directed repair30 Years of the Mineralocorticoid Receptor: Mineralocorticoid receptor antagonists: 60 years of research and development.New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension.Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications.Endogenous cardiotonic steroids in kidney failure: a review and an hypothesis.Mineralocorticoid receptor blockade-a novel approach to fight hyperkalaemia in chronic kidney diseaseRapid and MR-Independent IK1 Activation by Aldosterone during Ischemia-Reperfusion.Suppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR-4628.Mineralocorticoid receptor blocker eplerenone reduces pain behaviors in vivo and decreases excitability in small-diameter sensory neurons from local inflamed dorsal root ganglia in vitro.Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia.Novel drugs and intervention strategies for the treatment of chronic kidney disease.The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation.Marine natural product des-O-methyllasiodiplodin effectively lowers the blood glucose level in db/db mice via ameliorating inflammationTherapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.Key advances in antihypertensive treatment.Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy.Targeting the mineralocorticoid receptor in cardiovascular disease.Mineralocorticoid receptor modulators: a patent review (2007 - 2012).Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents.Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.Are there any new pharmacologic therapies on the horizon to better treat hypertension? A state-of-the-art paper.Aldosterone excess and resistant hypertension: investigation and treatment.Novel RAAS agonists and antagonists: clinical applications and controversies.Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease.Future drug discovery in renin-angiotensin-aldosterone system intervention.Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.Mineralocorticoid Receptor Antagonism in AKI: A New Hope?Gene regulation by glucocorticoid in ENaC-mediated Na⁺ transport by middle ear epithelial cells.Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling.Metabolomics for informing adverse outcome pathways: Androgen receptor activation and the pharmaceutical spironolactone.
P2860
Q21284671-60EA7022-565C-4052-81B2-D22703FA7814Q26746907-25BA9A97-970F-47FD-82E4-0770C66B936BQ27006954-4E3104AE-B9C1-4A60-84F9-48D1C8DCD396Q27016157-D453B4AF-F957-4DFF-B552-BFC77183648DQ27027792-94F28C49-3C6E-4433-9664-A571E3A86ABEQ28544460-C7E40C46-B932-4B93-9192-1B41C19FC47DQ30248429-D5D483DE-9ABF-4EBA-975C-6C8355E334A9Q33635645-CB75FA76-F777-4A48-A40E-A84A4242370DQ33846431-A7568BBB-1A35-41B6-9676-4F33E2EF461AQ34384580-4EE5EF09-D02E-4122-A604-14D31610E41BQ34684861-BC5CBCAE-9767-42BD-BC0C-22DDF70B5840Q35541172-B1B64D93-E14E-49E7-A181-DF2A11B03968Q35626544-20969E4E-ABDE-4AFC-A8A0-DC1A36A8FB92Q35722993-25EB6AE1-9D4A-42BC-991B-2D2B4EF27C2DQ35877719-8CA1A46E-6925-4409-88B1-B9C40ABE16C1Q36350685-8918E474-0D59-4E56-91CB-36069CD9567AQ36437145-F839E777-D4A9-4EDE-B370-CBBB9D282546Q36514942-CD0A9431-D15D-45F2-9F04-EA26F38BD738Q37219043-EEFF13BE-51CD-459F-8C50-26E72BCB38D2Q37622571-2914151B-5FF1-4AC7-A53A-E20E665F43EAQ37727721-0CF8F26F-C143-4343-B92F-9C85F3A1B02AQ37939427-8746C42B-EC75-4E2C-9506-C3A76F350291Q37995074-EAD45154-6ADC-42E7-9BAB-20CBED45644CQ38052452-5C25AC24-5CEF-45B1-830A-4EE8E55D95DDQ38074488-A5E4BCBA-1E75-4AF1-8ADE-D4DDDCFCDE16Q38161538-63AB0B9C-FB69-4E34-92F7-951F2FC64AADQ38181208-3D808BB5-5220-41B8-8AAA-39592F8A2001Q38182029-46C1CD4A-4D4F-4637-AA59-AFF1BE92E54BQ38208808-17F39407-E546-4CBD-A339-212E9D92AF2CQ38208961-BFF7457E-0EA5-4C80-9C2E-A2A414455BD1Q38349798-1B8A0BBE-298C-49D7-9454-8F24169F2E7DQ38658657-AFC65BFA-138E-42B0-BE55-0E875A8BFE3FQ38679303-BD3AE04E-6A5E-4B25-B426-72B2822746CFQ38850114-3463288D-8F74-4A05-8563-D1B514DF6971Q39199991-DAEEB72E-908E-4BA1-BF04-0215A692AED9Q42716993-7FA28DBD-3B4E-4B47-8FF3-2F32249ED30FQ43063544-4F1C8CD1-6DBD-462F-B443-5E07A5A01C3EQ46324500-69768C7C-9A46-4535-BCD0-79EBC6C6E340Q47647088-228E3193-A7B9-4378-B53A-335478CB8FB0Q47877788-6ED271C5-AF93-42C7-B2D1-5374E2F9632B
P2860
A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A new mode of mineralocorticoi ...... elective nonsteroidal molecule
@nl
A new mode of mineralocorticoi ...... lective nonsteroidal molecule.
@ast
A new mode of mineralocorticoi ...... lective nonsteroidal molecule.
@en
type
label
A new mode of mineralocorticoi ...... elective nonsteroidal molecule
@nl
A new mode of mineralocorticoi ...... lective nonsteroidal molecule.
@ast
A new mode of mineralocorticoi ...... lective nonsteroidal molecule.
@en
prefLabel
A new mode of mineralocorticoi ...... elective nonsteroidal molecule
@nl
A new mode of mineralocorticoi ...... lective nonsteroidal molecule.
@ast
A new mode of mineralocorticoi ...... lective nonsteroidal molecule.
@en
P2093
P2860
P3181
P356
P1476
A new mode of mineralocorticoi ...... lective nonsteroidal molecule.
@en
P2093
Alexander Hillisch
Elisabeth Pook
Jessica Huyet
Jérôme Fagart
Lars Bärfacker
Marie-Edith Rafestin-Oblin
Michel Fay
Peter Kolkhof
Stefan Schäfer
Ulrich Pleiss
P2860
P304
29932-29940
P3181
P356
10.1074/JBC.M110.131342
P407
P577
2010-07-22T00:00:00Z